ORIC® Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones

Core Insights - ORIC Pharmaceuticals, Inc. has announced early Phase 1b combination data for ORIC-944 and operational highlights for 2024, indicating progress in its clinical programs and collaborations [2][3] Clinical Development - ORIC-944 is being evaluated in combination with apalutamide for metastatic castration-resistant prostate cancer (mCRPC), showing promising early safety and efficacy data [1][4] - The company has initiated multiple cohorts for ORIC-114 in non-small cell lung cancer (NSCLC) and ORIC-944 in mCRPC, with expectations for seven data readouts over the next 18 months [3][12] - ORIC-944 demonstrated a clinical half-life of approximately 20 hours and a favorable safety profile, with deep prostate-specific antigen (PSA) decreases observed in patients [4][7] Financial Position - As of September 30, 2024, ORIC had cash, cash equivalents, and investments totaling $282.4 million, which is expected to fund operations into late 2026 [10] - The company completed a$125 million private investment in public equity (PIPE) financing, strengthening its cash position [3][12] Strategic Collaborations - ORIC has entered into clinical trial collaboration and supply agreements with Johnson & Johnson and Bayer to support ongoing trials for ORIC-944 and ORIC-114 [1][12] - The collaborations aim to evaluate ORIC-114 in combination with amivantamab for first-line treatment of NSCLC patients with specific mutations [1][12] Upcoming Milestones - The company anticipates initiating registrational trials for ORIC-114 in the second half of 2025 and for ORIC-944 in early 2026 [1][3][12] - Key upcoming data milestones include various cohorts for ORIC-114 and ORIC-944, with specific timelines outlined for 2025 and 2026 [12]